U.S. markets open in 4 hours 54 minutes
  • S&P Futures

    3,917.50
    -5.00 (-0.13%)
     
  • Dow Futures

    31,944.00
    +28.00 (+0.09%)
     
  • Nasdaq Futures

    13,217.50
    -84.50 (-0.64%)
     
  • Russell 2000 Futures

    2,297.10
    +12.00 (+0.53%)
     
  • Crude Oil

    63.48
    +0.26 (+0.41%)
     
  • Gold

    1,786.60
    -11.30 (-0.63%)
     
  • Silver

    27.92
    +0.06 (+0.22%)
     
  • EUR/USD

    1.2217
    +0.0049 (+0.40%)
     
  • 10-Yr Bond

    1.3890
    0.0000 (0.00%)
     
  • Vix

    21.88
    -1.23 (-5.32%)
     
  • GBP/USD

    1.4161
    +0.0020 (+0.14%)
     
  • USD/JPY

    106.1000
    +0.2180 (+0.21%)
     
  • BTC-USD

    49,115.85
    -1,719.60 (-3.38%)
     
  • CMC Crypto 200

    981.39
    -13.27 (-1.33%)
     
  • FTSE 100

    6,690.02
    +31.05 (+0.47%)
     
  • Nikkei 225

    30,168.27
    +496.57 (+1.67%)
     

AcelRx Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

REDWOOD CITY, Calif., June 1, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced that management will be providing an overview of the business and company updates at the Jeffries Virtual Healthcare Conference to be held June 2 at 1:30 p.m. ET (10:30 a.m. PT). A live webcast link of the event can be found on the Company's website at http://ir.acelrx.com/upcoming-events. Management will also be hosting one-on-one investor meetings throughout the day.

For those not available to listen to the live webcast, a replay will be archived for 90 days and available through the Investors page on www.acelrx.com.

About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The Company has one approved product in the U.S., DSUVIA® (sufentanil sublingual tablet, 30 mcg), known as DZUVEO in Europe, indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings, and one product candidate, Zalviso® (sufentanil sublingual tablet system, SST system, 15 mcg) being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings. DZUVEO and Zalviso are both approved products in Europe. Zalviso is not approved in the U.S. For additional information about AcelRx, please visit www.acelrx.com.

AcelRx logo. (PRNewsFoto/AcelRx Pharmaceuticals, Inc.) (PRNewsfoto/AcelRx Pharmaceuticals, Inc.)
AcelRx logo. (PRNewsFoto/AcelRx Pharmaceuticals, Inc.) (PRNewsfoto/AcelRx Pharmaceuticals, Inc.)
Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-to-present-at-the-jefferies-virtual-healthcare-conference-301068872.html

SOURCE AcelRx Pharmaceuticals, Inc.